Back to List View Graph View

SARS-CoV-2

SARS-CoV-2 is a betacoronavirus and the causative agent of COVID-19, the respiratory disease that emerged as a global pandemic.

Where the papers sit

35 papers from the last 6 months study SARS-CoV-2 directly · updated from PubMed 16 Nov 2026

  • COVID-19 Vaccine Immunity

    Vaccine design is moving toward broader, more durable protection through tandem or divergent RBDs, intranasal delivery, virus-like particles, and combined mRNA formulations. Antibody and T-cell studies repeatedly assess neutralization breadth, memory, isotype profiles, and protection against variants. Booster strategies are increasingly evaluated in vulnerable people, including those with immune-mediated inflammatory disease. Access in rural sub-Saharan Africa remains a practical constraint alongside the immunological advances.

    16 papers · 45.7%

  • Broad-Spectrum Antiviral Discovery

    Antiviral discovery is moving from single-virus screening toward broad respiratory-virus coverage and structure-guided SARS-CoV-2 optimization. Cyclophilin inhibitors, Amaryllidaceae alkaloids, ALK inhibitors, and nucleoside analog designs are tested against influenza and coronaviruses. Mpro programs refine pyrimidine, thiadiazole, and 6-methoxypyrimidine scaffolds, while docking and machine learning prioritize candidates. Most evidence remains biochemical, computational, or early preclinical, leaving selectivity and clinical translation open.

    12 papers · 34.3%

  • CRISPR-Based Molecular Detection

    Rapid CRISPR/Cas12a detection is moving toward one-pot workflows that harmonize amplification and cleavage for sensitive, robust testing. Cas12a-G4 DNAzyme platforms broaden the targets beyond nucleic acids while preserving rapid readouts. Wastewater genomic surveillance extends molecular detection into population-level monitoring of viral diversity and transmission. The main open question is how consistently these platforms perform across complex samples and field settings.

    3 papers · 8.6%

  • Others — COVID-19 Translational Biology

    COVID-19 translational work here spans antioxidant and immunomodulatory treatment, ACE2-directed intracellular delivery, stroke-thrombus pathology, and qPCR biodistribution measurement. Hypericum perforatum and ACE2-PNA conjugates are explored as antiviral interventions, while cerebral hemoglobin and iron suggest mechanisms for COVID-19-associated stroke. Assay validation supports tracking plasmid DNA distribution rather than a therapeutic endpoint. These studies share SARS-CoV-2 relevance but do not establish a single therapeutic direction.

    4 papers · 11.4%

Papers

The 35 papers from the last 6 months that study SARS-CoV-2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

COVID-19 Vaccine Immunity (16)
  1. Evaluation of Physics-Based Pose Prediction and the Role of Receptor Flexibility in a Community Antiviral Blind Challenge. Journal of chemical information and modeling · 26 Oct 2026 PMID 42929583
  2. Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19. Human vaccines & immunotherapeutics · 6 Oct 2026 PMID 42836482
  3. Availability and accessibility of SARS-CoV-2 vaccines among rural populations in sub-Saharan Africa: a systematic review and meta-analysis protocol. BMJ open · 24 Sept 2026 PMID 42785944
  4. Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters. Journal of virology · 24 Sept 2026 PMID 42782150
  5. Exploring the potential of Ayush-64 in mitigation of post-coronavirus disease of 2019 complications of Delta variant of severe acute respiratory syndrome coronavirus 2. Phytomedicine : international journal of phytotherapy and phytopharmacology · 10 Sept 2026 PMID 42721823
  6. A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 7 Sept 2026 PMID 42702867
  7. Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine · 5 Sept 2026 PMID 42700748
  8. Platelet-derived serotonin drives age-related lung pathology in SARS-CoV-2 infection. Science immunology · 28 Aug 2026 PMID 42664308
  9. Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen. Proceedings of the National Academy of Sciences of the United States of America · 26 Aug 2026 PMID 42647127
  10. Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice. Vaccine · 12 Aug 2026 PMID 42585813
  11. The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants. JCI insight · 11 Aug 2026 PMID 42579364
  12. Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca. Viral immunology · 7 Aug 2026 PMID 42565654
  13. Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine · 30 Jul 2026 PMID 42531981
  14. Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
  15. A comparison of alternative vaccination strategies for protecting those vulnerable to illness, hospitalization, or death upon infection with SARS-CoV-2. Journal of theoretical biology · 11 Jul 2026 PMID 42435934
  16. Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case-control study using linked primary-care, hospitalisation and mortality data from England. RMD open · 3 Jul 2026 PMID 42399080
Broad-Spectrum Antiviral Discovery (12)
  1. Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus. Science advances · 7 Oct 2026 PMID 42842678
  2. Genomic surveillance of SARS-CoV-2 in Tunisia during the omicron era: insights from the national influenza & other respiratory viruses laboratory. Virology journal · 17 Sept 2026 PMID 42750054
  3. Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 Mpro Inhibitors. ACS infectious diseases · 11 Sept 2026 PMID 42725964
  4. Discovery of a new class based on 6-methoxypyrimidine as efficient low weight reversible inhibitors of SARS-CoV-2 main protease (Mpro) with antiviral activity. Bioorganic chemistry · 8 Sept 2026 PMID 42710401
  5. Network pharmacology, and molecular docking studies for two flavonoid compounds isolated from Dodonaea viscosa towards SARS-CoV-2 infection and loaded in lipid nanoparticles. Artificial cells, nanomedicine, and biotechnology · 7 Sept 2026 PMID 42702742
  6. SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases. Mycopathologia · 18 Aug 2026 PMID 42611121
  7. Machine learning-based prediction of SARS-CoV-2 bioactivity: integrating IC50 regression and activity classification using multi-task neural networks. BMC bioinformatics · 6 Aug 2026 PMID 42557548
  8. Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467054
  9. Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
  10. Grammatical evolution-based design of nucleotic analogs for SARS-CoV-2's replication-transcription complex. Physical chemistry chemical physics : PCCP · 1 Jul 2026 PMID 42383721
  11. Structure-guided optimization of N-(5-((2-oxopropyl) thio)-1,3,4-thiadiazol-2-yl) propionamide frameworks as potent SARS-CoV-2 Mpro inhibitor for treating coronavirus disease. Bioorganic chemistry · 18 Jun 2026 PMID 42314596
  12. Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus research · 9 Jun 2026 PMID 42263913
CRISPR-Based Molecular Detection (3)
  1. Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024. Microbiology spectrum · 29 Sept 2026 PMID 42808729
  2. Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
  3. Universal CRISPR/Cas12a-G4 DNAzyme biosensing platform for rapid detection of nucleic acid and non-nucleic acid targets. The Analyst · 1 Sept 2026 PMID 42677878
Others — COVID-19 Translational Biology (4)
  1. Triple-Action Antioxidant, Antiviral, and Immunomodulatory Effects of Hypericum perforatum Against SARS-CoV-2 Using Chemical-Based and In Vitro Methods. Plant foods for human nutrition (Dordrecht, Netherlands) · 1 Oct 2026 PMID 42821038
  2. High levels of cell-free hemoglobin and iron in cerebral thrombi of pre-Omicron COVID-19 stroke patients: novel drivers of SARS-CoV-2-induced prothrombotic state. Acta neuropathologica · 29 Aug 2026 PMID 42667425
  3. Development and fit-for-purpose validation of a qPCR assay for biodistribution assessment of plasmid DNA following electrode-needle device-assisted intramuscular electroporation. International journal of pharmaceutics · 19 Aug 2026 PMID 42617896
  4. ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604

By study type

Clinical trials (1)
  1. Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine · 30 Jul 2026 PMID 42531981
Observational studies and case reports (1)
  1. Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case-control study using linked primary-care, hospitalisation and mortality data from England. RMD open · 3 Jul 2026 PMID 42399080
Human data, design not indexed (14)
  1. Evaluation of Physics-Based Pose Prediction and the Role of Receptor Flexibility in a Community Antiviral Blind Challenge. Journal of chemical information and modeling · 26 Oct 2026 PMID 42929583
  2. Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19. Human vaccines & immunotherapeutics · 6 Oct 2026 PMID 42836482
  3. Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024. Microbiology spectrum · 29 Sept 2026 PMID 42808729
  4. Availability and accessibility of SARS-CoV-2 vaccines among rural populations in sub-Saharan Africa: a systematic review and meta-analysis protocol. BMJ open · 24 Sept 2026 PMID 42785944
  5. Genomic surveillance of SARS-CoV-2 in Tunisia during the omicron era: insights from the national influenza & other respiratory viruses laboratory. Virology journal · 17 Sept 2026 PMID 42750054
  6. Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics. Proceedings of the National Academy of Sciences of the United States of America · 9 Sept 2026 PMID 42715083
  7. Universal CRISPR/Cas12a-G4 DNAzyme biosensing platform for rapid detection of nucleic acid and non-nucleic acid targets. The Analyst · 1 Sept 2026 PMID 42677878
  8. High levels of cell-free hemoglobin and iron in cerebral thrombi of pre-Omicron COVID-19 stroke patients: novel drivers of SARS-CoV-2-induced prothrombotic state. Acta neuropathologica · 29 Aug 2026 PMID 42667425
  9. SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases. Mycopathologia · 18 Aug 2026 PMID 42611121
  10. Comparative Analysis of Nucleocapsid- and Spike-Specific Isotype Humoral Immune Responses Following Natural SARS-CoV-2 Infection and Vaccination with Sinopharm, Sinovac, and AstraZeneca. Viral immunology · 7 Aug 2026 PMID 42565654
  11. Machine learning-based prediction of SARS-CoV-2 bioactivity: integrating IC50 regression and activity classification using multi-task neural networks. BMC bioinformatics · 6 Aug 2026 PMID 42557548
  12. A comparison of alternative vaccination strategies for protecting those vulnerable to illness, hospitalization, or death upon infection with SARS-CoV-2. Journal of theoretical biology · 11 Jul 2026 PMID 42435934
  13. Grammatical evolution-based design of nucleotic analogs for SARS-CoV-2's replication-transcription complex. Physical chemistry chemical physics : PCCP · 1 Jul 2026 PMID 42383721
  14. Structure-guided optimization of N-(5-((2-oxopropyl) thio)-1,3,4-thiadiazol-2-yl) propionamide frameworks as potent SARS-CoV-2 Mpro inhibitor for treating coronavirus disease. Bioorganic chemistry · 18 Jun 2026 PMID 42314596
Preclinical: animal, cell and lab studies (18)
  1. Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus. Science advances · 7 Oct 2026 PMID 42842678
  2. Triple-Action Antioxidant, Antiviral, and Immunomodulatory Effects of Hypericum perforatum Against SARS-CoV-2 Using Chemical-Based and In Vitro Methods. Plant foods for human nutrition (Dordrecht, Netherlands) · 1 Oct 2026 PMID 42821038
  3. Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters. Journal of virology · 24 Sept 2026 PMID 42782150
  4. Exploring the Pyrimidine Scaffold for the Development of SARS-CoV-2 Mpro Inhibitors. ACS infectious diseases · 11 Sept 2026 PMID 42725964
  5. Exploring the potential of Ayush-64 in mitigation of post-coronavirus disease of 2019 complications of Delta variant of severe acute respiratory syndrome coronavirus 2. Phytomedicine : international journal of phytotherapy and phytopharmacology · 10 Sept 2026 PMID 42721823
  6. Discovery of a new class based on 6-methoxypyrimidine as efficient low weight reversible inhibitors of SARS-CoV-2 main protease (Mpro) with antiviral activity. Bioorganic chemistry · 8 Sept 2026 PMID 42710401
  7. Network pharmacology, and molecular docking studies for two flavonoid compounds isolated from Dodonaea viscosa towards SARS-CoV-2 infection and loaded in lipid nanoparticles. Artificial cells, nanomedicine, and biotechnology · 7 Sept 2026 PMID 42702742
  8. Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine · 5 Sept 2026 PMID 42700748
  9. Platelet-derived serotonin drives age-related lung pathology in SARS-CoV-2 infection. Science immunology · 28 Aug 2026 PMID 42664308
  10. Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen. Proceedings of the National Academy of Sciences of the United States of America · 26 Aug 2026 PMID 42647127
  11. Development and fit-for-purpose validation of a qPCR assay for biodistribution assessment of plasmid DNA following electrode-needle device-assisted intramuscular electroporation. International journal of pharmaceutics · 19 Aug 2026 PMID 42617896
  12. Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice. Vaccine · 12 Aug 2026 PMID 42585813
  13. The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants. JCI insight · 11 Aug 2026 PMID 42579364
  14. ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2. Molecular biomedicine · 3 Aug 2026 PMID 42545604
  15. Broad and durable protection against SARS-CoV-2 and SARS-CoV by an intranasal chimpanzee adenovirus vaccine expressing tandem RBDs and nucleocapsid. PLoS pathogens · 24 Jul 2026 PMID 42497177
  16. Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467054
  17. Discovery of broad-spectrum antiviral activity in Amaryllidaceae alkaloids. Biochemical and biophysical research communications · 8 Jul 2026 PMID 42419220
  18. Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus research · 9 Jun 2026 PMID 42263913
Unclassified: not yet indexed with MeSH (1)
  1. A Dual-Membrane Biomimetic Nanoplatform Enables Triple-Modal Therapy Against SARS-CoV-2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 7 Sept 2026 PMID 42702867